Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of subcutaneous amivantamab regimens in EGFR-mutated advanced or metastatic non-small cell lung cancer
ISRCTN11527992Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of amivantamab in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (6 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective response rate by investigator assessment, Number of participants with adverse events and 3 more. Started Oct 2022; status: completed.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN11527992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11527992.